Risk for Breast Cancer Examined After False-Positive Mammogram
The risk for developing breast cancer after a false-positive mammography result varies with age,...
Read More
Oncology
Mortality Higher for Black Patients Receiving Neoadjuvant Chemo for Breast Cancer
For patients with early-stage breast cancer treated with neoadjuvant chemotherapy (NACT), Black...
Read More
ASTRO Issues Guidance Related to Partial Breast Irradiation
In a clinical practice guideline published in Practical Radiation Oncology, the American Society...
Read More
Atezolizumab Monotherapy Found Comparable to Chemotherapy in Urothelial Carcinoma
In a study comparing atezolizumab monotherapy with platinum-based chemotherapy in advanced...
Read More
#VisualAbstract: Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival
1. Mirvetuximab soravtansine-gynx (MIRV) significantly improved progression-free survival,...
Read More
Family caregivers of patients with advanced cancer show variations in spiritual coping levels
1. In this cross-sectional study, family caregivers of patients with advanced cancer had moderate...
Read More
Rituximab maintenance therapy following autologous stem cell transplant increased survival in young patients with mantle-cell lymphoma
1. In patients with mantle-cell lymphoma who responded to induction therapy and autologous stem...
Read More
Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the...
Read More
Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival
1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival,...
Read More
Atezolizumab Monotherapy vs Chemotherapy In Advanced Urothelial Carcinoma
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab...
Read More
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) prescribed for type 2 diabetes are associated with reduced colorectal cancer (CRC) risk compared to other antidiabetic agents
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as...
Read More
Carrier status of an actionable gene is associated with reduced life span in large Icelandic study
1. In this cross-sectional study, having carrier status of actionable genes identified by the...
Read More
Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related...
Read More
Specific viruses may be associated with increased risk and worse outcomes of ovarian cancer
1. This retrospective cohort study tested ovarian tumors for 113 viruses and found six viruses of...
Read More
Inflammatory tongue conditions associated with increased risk of oral tongue cancer
1. In this case-control study, those with tongue cancer were found to have ten-fold increases in...
Read More
T2D Is Associated With Risk for Colorectal Cancer
Individuals with diabetes who undergo colorectal cancer (CRC) screening, specifically colonoscopy, may be able to mitigate the risk for CRC.
Read More
Q&A: Integrative Therapies for Adults With Cancer With Anxiety & Depression
An evidence-based guideline to help healthcare professionals give sound advice regarding mental health to people with cancer is sorely needed.
Read More
Erdafitinib or Chemotherapy in Advanced Pre-Treated Urothelial Carcinoma
1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the...
Read More
Pembrolizumab and carboplatin plus docetaxel treatment regimens may provide options for patients with triple-negative breast cancer who are ineligible for anthracycline-based regimens
1. Overall pathologic complete response to treatment of triple-negative breast cancer with a...
Read More
Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
1. Progression-free survival was not reached in the selpercatinib group and was 16.8 months in the...
Read More